TIP_link_300x300.jpg
Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners
September 27, 2023 10:12 ET | The Insight Partners
Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...
Figure 1
Theralase® Releases FY2022 Audited Financial Statements
April 26, 2023 18:01 ET | Theralase Technologies Inc.
TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
theralase_logo_destroying_cancer.png
Theralase® Phase Ib NMIBC Clinical Study Published
June 21, 2022 07:00 ET | Theralase Technologies Inc.
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Moderated by Benjamin Rehberg, Managing Director & Senior Partner at BCG
CAST Founder to Speak at BCG-led Virtual Software Intelligence Forum 2022
January 10, 2022 10:07 ET | CAST Software Inc.
NEW YORK and PARIS, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CAST Founder & CEO, Vincent Delaroche, will be joining Benjamin Rehberg, BCG Senior Partner & Head of Technology Practice NA, as he...
theralase_logo_destroying_cancer.png
Theralase Releases 3Q21 Financial Statements and Newsletter
November 29, 2021 18:00 ET | Theralase Technologies Inc.
TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
July 30, 2021 - ROSEN LOGO.jpg
SESN NOTICE: Rosen, Trusted Investor Counsel, Encourages Sesen Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 18 Deadline in Securities Class Action – SESN
October 13, 2021 18:15 ET | The Rosen Law Firm PA
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sesen Bio, Inc. (NASDAQ: SESN) between December 21, 2020...
Study II Clinical Data (Preliminary)*
Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter
August 30, 2021 18:15 ET | Theralase Technologies Inc.
TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the research...
theralase_logo_destroying_cancer.png
Theralase® Launches Seventh US-Based Clinical Study Site and Treats First Patient in the US
June 11, 2021 07:00 ET | Theralase Technologies Inc.
TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
BCG_LOCKUP_CMYK_GREEN (1)_Page_1.jpg
Boston Consulting Group Is Named Top Leader of Organization Strategy Consulting Worldwide
December 17, 2018 10:01 ET | BCG
BOSTON, Dec. 17, 2018 (GLOBE NEWSWIRE) -- ALM Intelligence has named Boston Consulting Group (BCG) the top leader in organization strategy worldwide for the second year in a row. The latest edition...
BCG_LOCKUP_CMYK_GREEN (1)_Page_1.jpg
In Times of Volatility and Uncertainty, Companies Should Refocus on the Real Essence of Value Creation
November 27, 2018 00:01 ET | BCG
BOSTON, Nov. 27, 2018 (GLOBE NEWSWIRE) -- During the ten-year bull market, companies’ share prices seemed almost to soar at will: ten years of uninterrupted economic growth and low interest rates...